TY  - RPRT
TI  - Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.
AU  - Saichun Zhang
AU  - Yunjuan Gu
AU  - Yu Cheng
AU  - Ying Hu
AU  - Bing Li
AU  - Agustina Alvarez
AU  - Felipe Lauand
AU  - Lydie Melas-Melt
AU  - Minlu Zhang
AU  - Yini Jiang
AU  - Qin Du
AU  - Lei Kang
AU  - Yiming Mu
AU  - Weijun Gu
AU  - Hongyu Kuang
PY  - 2026
DO  - 10.1111/dom.71057
UR  - https://pubmed.ncbi.nlm.nih.gov/42473266/
ID  - 42473266
ER  -